Hepatitis B viraemia: Its heritability and association with common genetic variation in the interferon γ signalling pathway

Gut

Volumn 60, Issue 1, 2011, Pages 99-107

  Huang, Hsuan Hao ^a   Shih, Wei Liang ^a   Li, Yi Hsiu ^a   Wu, Chih Feng ^a   Chen, Pei Jer ^b   Lin, Chih Lin ^c   Liu, Chun Jen ^b   Liaw, Yun Fan ^d   Lin, Shi Ming ^d   Lee, Shou Dong ^e   Yu, Ming Whei ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; FEMALE; GENETIC VARIABILITY; HEPATITIS B VIRUS; HERITABILITY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIREMIA; VIRUS LOAD;

EID: 84984559313     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.207670     Document Type: Article

References (55)

1. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-92.
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52.
4. Sung FY, Jung CM, Wu CF, et al. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology 2009;137:1687-97.
5. Wu CF, Yu MW, Lin CL, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29:106-12.
6. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265-72.
7. Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-803.
8. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008;26:177-82.
9. Xu Z, Yen TS, Wu L, et al. Enhancement of hepatitis B virus replication by its X protein in transgenic mice. J Virol 2002;76:2579-84.
10. Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001;294:2376-8.
11. Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002;299:88-99.
12. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007;46:531-8.
13. Rehermann B. Immune responses in hepatitis B virus infection. Semin Liver Dis 2003;23:21-38.
14. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36.
15. McClary H, Koch R, Chisari FV, et al. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000;74:2255-64.
16. van Nunen AB, Pontesilli O, Uytdehaag F, et al. Suppression of hepatitis B virus replication mediated by hepatitis A-induced cytokine production. Liver 2001;21:45-9.
17. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
18. Kakimi K, Guidotti LG, Koezuka Y, et al. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000;192:921-30.
19. Shtrichman R, Samuel CE. The role of gamma interferon in antimicrobial immunity. Curr Opin Microbiol 2001;4:251-9.
20. Robek MD, Boyd BS, Wieland SF, et al. Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci U S A 2004;101:1743-7.
21. Filipe-Santos O, Bustamante J, Chapgier A, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006;18:347-61.
22. Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004;364:2113-21.
23. Thye T, Burchard GD, Nilius M, et al. Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. Am J Hum Genet 2003;72:448-53.
24. Chapgier A, Kong XF, Boisson-Dupuis S, et al. A partial form of recessive STAT1 deficiency in humans. J Clin Invest 2009;119:1502-14.
25. Huang Y, Yang H, Borg BB, et al. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A 2007;104:985-90.
26. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994;17:71-91.
27. Yu MW, Chang HC, Liaw YF, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92:1159-64.
28. Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661-6.
29. Yeo W, Mo FK, Chan SL, et al. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007;45:1382-9.
30. Yu MW, Shih WL, Lin CL, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol 2008;26:5576-82.
31. Abecasis GR, Cookson WO, Cardon LR. The power to detect linkage disequilibrium with quantitative traits in selected samples. Am J Hum Genet 2001;68:1463-74.
32. de Bakker PI, Yelensky R, Pe'er I, et al. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-23.
33. O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 1998;63:259-66.
34. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5. (Pubitemid 40202029)
35. Donner A, Koval JJ. The estimation of intraclass correlation in the analysis of family data. Biometrics 1980;36:19-25.
36. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998;62:1198-211.
37. Lange C, DeMeo D, Silverman EK, et al. PBAT: tools for family-based association studies. Am J Hum Genet 2004;74:367-9.
38. Abecasis GR, Cardon LR, Cookson WO. A general test of association for quantitative traits in nuclear families. Am J Hum Genet 2000;66:279-92.
39. Smith NL, Hindorff LA, Heckbert SR, et al. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 2007;297:489-98.
40. Nicodemus KK, Luna A, Shugart YY. An evaluation of power and type I error of single-nucleotide polymorphism transmission/disequilibrium-based statistical methods under different family structures, missing parental data, and population stratification. Am J Hum Genet 2007;80:178-85.
41. Shih WL, Yu MW, Chen PJ, et al. Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. Oncogene 2006;25:3219-24.
42. Yu MW, Yang YC, Yang SY, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001;93:1644-51.
43. Yu MW, Yang SY, Pan IJ, et al. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2003;95:1485-88.
44. Chen CC, Yang SY, Liu CJ, et al. Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol 2005;34:1310-18.
45. Yoon YJ, Chang HY, Ahn SH, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008;29:1192-6.
46. Zhai Y, Zhou G, Deng G, et al. Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 2006;130:2001-9.
47. Pasquetto V, Wieland SF, Uprichard SL, et al. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 2002;76:5646-53.
48. Tishon A, Lewicki H, Rall G, et al. An essential role for type 1 interferon-gamma in terminating persistent viral infection. Virology 1995;212:244-50.
49. Frodsham AJ, Zhang L, Dumpis U, et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci U S A 2006;103:9148-53.
50. Doyle SE, Schreckhise H, Khuu-Duong K, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896-906.
51. Najarro P, Traktman P, Lewis JA. Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol 2001;75:3185-96.
52. Lin RJ, Chang BL, Yu HP, et al. Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism. J Virol 2006;80:5908-18.
53. Liu WJ, Wang XJ, Mokhonov VV, et al. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J Virol 2005;79:1934-42.
54. Shaw ML, García-Sastre A, Palese P, et al. Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol 2004;78:5633-41.
55. Wu M, Xu Y, Lin S, et al. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J Gen Virol 2007;88:3260-9. (Pubitemid 350201835)